The impact of combined pulmonary fibrosis and emphysema on mortality

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 8, 2011, Pages 1111-1116

  Lee, C H ^a   Kim, H J ^b   Park, C M ^c   Lim, K Y ^d   Lee, J Y ^e   Kim, D J ^c   Yeon, J H ^c   Hwang, S S ^f   Kim, D K ^a   Lee, S M ^e   Yim, J J ^e   Yang, S C ^e   Yoo, C G ^e   Chung, H S ^a   Kim, Y W ^e   Han, S K ^e   Shim, Young Soo ^e  

^a Seoul National University Boramae Hospital   (South Korea)

^b Konkuk University Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d National Cancer Center   (South Korea)

^e Lung Institute   (South Korea)

^f Inha University School of Medicine   (South Korea)

Author keywords

Emphysema; Mortality; Pulmonary fibrosis

Indexed keywords

ADULT; AGED; ARTICLE; BODY HEIGHT; CAUSE OF DEATH; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FORCED VITAL CAPACITY; HUMAN; HYPERTENSION; LUNG EMPHYSEMA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; SURVIVAL RATE; THORAX RADIOGRAPHY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COMORBIDITY; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79960425217     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0491     Document Type: Article

References (32)

1. Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med 1990; 84: 365-369. (Pubitemid 20287410)
2. Hiwatari N, Shimura S, Takishima T. Pulmonary emphysema followed by pulmonary fibrosis of undetermined cause. Respiration 1993; 60: 354-358. (Pubitemid 23348646)
3. Doherty M J, Pearson M G, O'Grady E A, Pellegrini V, Calverley P M. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997; 52: 998-1002.
4. Cottin V, Nunes H, Brillet P Y, et al. Combined pulmonary fi- brosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26: 586-593. (Pubitemid 41448654)
5. Grubstein A, Bendayan D, Schactman I, Cohen M, Shitrit D, Kramer M R. Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature. Respir Med 2005; 99: 948-954. (Pubitemid 40796537)
6. Mura M, Zompatori M, Pacilli A M, Fasano L, Schiavina M, Fabbri M. The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis. Respir Care 2006; 51: 257-265. (Pubitemid 46888402)
7. Cottin V, Le Pavec J, Prevot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35: 105-111.
8. Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136: 10-15.
9. Foster W L Jr, Gimenez E I, Roubidoux M A, et al. The emphysemas: radiologic-pathologic correlations. Radiographics 1993; 13: 311-328.
10. Hansell D M, Bankier A A, MacMahon H, McLoud T C, Muller N L, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246: 697-722.
11. Kinsella M, Muller N L, Abboud R T, Morrison N J, DyBuncio A. Quantitation of emphysema by computed tomography using a 'density mask' program and correlation with pulmonary function tests. Chest 1990; 97: 315-321.
12. Muller N L, Staples C A, Miller R R, Abboud R T. 'Density mask'. An objective method to quantitate emphysema using computed tomography. Chest 1988; 94: 782-787.
13. Hersh C P, Washko G R, Jacobson F L, et al. Interobserver variability in the determination of upper lobe-predominant emphysema. Chest 2007; 131: 424-431. (Pubitemid 46280402)
14. Simonneau G, Robbins I M, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (Suppl): S43-S54.
15. Cottin V, Cordier J F. The syndrome of combined pulmonary fibrosis and emphysema. Chest 2009; 136: 1-2.
16. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med 1994; 150: 833-852. (Pubitemid 24291518)
17. Salvaterra C G, Rubin L J. Investigation and management of pulmonary hypertension in chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148: 1414-1417. (Pubitemid 23326048)
18. Berger M, Haimowitz A, Van Tosh A, Berdoff R L, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985; 6: 359-365. (Pubitemid 15048812)
19. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-664.
20. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242. (Pubitemid 41697286)
21. Davies H R, Richeldi L, Walters E H. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003: CD003134.
22. Cottin V, Donsbeck A V, Revel D, Loire R, Cordier J F. Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients. Am J Respir Crit Care Med 1998; 158: 1286-1293. (Pubitemid 28489034)
23. Kondoh Y, Taniguchi H, Yokoi T, et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J 2005; 25: 528-533. (Pubitemid 40331185)
24. Trouillet J L, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157: 531-539. (Pubitemid 28090546)
25. Gaynes R. Health care-associated bloodstream infections: a change in thinking. Ann Intern Med 2002; 137: 850-851. (Pubitemid 35334455)
26. Gerrard J G. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults. Med J Aust 1995; 162: 233-235.
27. Ognibene F P, Shelhamer J H, Hoffman G S, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995; 151: 795-799.
28. Rodriguez M, Fishman J A. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17: 770-782. (Pubitemid 39372516)
29. Kollef K E, Schramm G E, Wills A R, Reichley R M, Micek S T, Kollef M H. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008; 134: 281-287.
30. Rello J, Rue M, Jubert P, et al. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997; 25: 1862-1867. (Pubitemid 27483968)
31. Drummond M B, Dasenbrook E C, Pitz M W, Murphy D J, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and metaanalysis. JAMA 2008; 300: 2407-2416.
32. Sin D D, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712-719.